Literature DB >> 3858595

Relationship between thiol depletion and chemosensitization in a transplantable murine bladder tumor.

P Tomashefsky, M Astor, R D White.   

Abstract

The effect of pretreating the C3H/He mouse MBT-2 tumor with diethyl maleate (DEM), buthionine-S R-sulfoximine (BSO), or misonidazole (MISO) before administration of cyclophosphamide (CTX) was studied with the use of tumor volume-doubling time delay as an endpoint. The kinetics of glutathione (GSH) depletion and regeneration in the tumor and in the host liver were determined after treatment with the thiol-depleting agents. CTX was administered at appropriate time points. MISO was the most effective chemosensitizer at a time point at which tumor GSH content was 80-85% of the control value. Both BSO and DEM were chemosensitizers in relation to the degree they had reduced tumor GSH levels. This chemosensitization was significant at 50% GSH reduction. By combining MISO and BSO at doses lower than previously used for each agent alone, highly effective sensitization of subsequent CTX was obtained.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3858595

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  3 in total

1.  Inhibition of cisplatin-induced nephrotoxicity in rats by buthionine sulfoximine, a glutathione synthesis inhibitor.

Authors:  R D Mayer; K E Lee; A T Cockett
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Effect of diethyldithiocarbamate on toxicity of doxorubicin, cyclophosphamide and cis-diamminedichloroplatinum (II) on mice haemopoietic progenitor cells.

Authors:  I M Pannacciulli; R A Lerza; G V Bogliolo; M P Mencoboni; A G Saviane
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

3.  Combined effect of buthionine sulfoximine and cyclophosphamide upon murine tumours and bone marrow.

Authors:  K Ono; C Komuro; K Tsutsui; Y Shibamoto; T Nishidai; M Takahashi; M Abe; D C Shrieve
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.